Impax Laboratories announced the launch of Sevelamer Carbonate Tablets, the generic version of Genzyme’s Renvela. The release is under the terms of a settlement agreement with Genzyme to license a specified amount of an authorized generic version of Renevla tablets. Impax’s Abbreviated New Drug Application (ANDA) for generic Renvela is currently pending review by the FDA.
Renvela is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. Renvela binds phosphate in the GI tract thus decreasing absorption and lowering the phosphate concentration in the serum.
Sevelamer Carbonate Tablets are available in 800mg strength.
For more information call (877) 994-6729 or visit ImpaxLabs.com.